Their possible adverse effects on depleting CD73+ effector cells and on the development of immunologic memory have to be carefully examined to establish the beneficial effects of anti‐CD73 antibody treatment regimens in tumour therapies. The gene discussed is NT5E; the disease is neoplasm.